Preventing adverse events during paediatric cancer treatment: A multi-site hybrid randomised controlled trial of catheter lock solutions (The CLOCK trial)

Not Applicable

Recruiting

• Conditions: Paediatric Cancer; Central vascular access device (CVAD) related adverse events; Cancer - Any cancer

• Registration Number: ACTRN12622000499785
• Lead Sponsor: niversity of Queensland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-03-29
• Last Update Posted: 15 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 720

Inclusion Criteria

Children (<18 years) with an oncological or malignant haematological condition who have a CVAD in situ (including peripherally inserted central catheters [PICCs], tunnelled (cuffed or non-cuffed) [e.g. Hickman®; Becton Dickinson, US] and totally implanted [e.g. PORT-A-CATH®; Smith Medical, US] will be eligible for inclusion. ; Children (<18 years) with an oncological or malignant haematological condition who have a CVAD in situ (including peripherally inserted central catheters [PICCs], tunnelled (cuffed or non-cuffed) [e.g. Hickman®; Becton Dickinson, US] and totally implanted [e.g. PORT-A-CATH®; Smith Medical, US] will be eligible for inclusion.

Exclusion Criteria

-End-of-life pathway/measures at recruitment
-Pre-existing coagulopathic condition not related to current diagnosis or treatment (e.g. Haemophilia A and B or other factor deficiency; Immune Thrombocytopenic Purpura (ITP); Von Willebrand’s disease)
-Known allergy to heparin or T-EDTA
; -End-of-life pathway/measures at recruitment
-Pre-existing coagulopathic condition not related to current diagnosis or treatment (e.g. Haemophilia A and B or other factor deficiency; Immune Thrombocytopenic Purpura (ITP); Von Willebrand’s disease)
-Known allergy to heparin or T-EDTA

Study & Design

• Study Type: Interventional
• Study Design: Not specified